Portco highlight: 32 Biosciences

health

portal

32 Biosciences raised capital through Republic Portal in Q1 2025

In portfolio since	Q2 2023
invested amount	$509,498
Note eligibility	100% of NET profit if sold

Many chronic conditions, from infections to inflammation, are increasingly tied to disruptions in the gut microbiome. Yet today, there are no standardized, FDA-approved clinical diagnostics widely used to measure microbiome function or to intervene early.

32 Biosciences was founded in 2023 to close that gap. The company is building a unified platform for gut health: combining diagnostics, therapeutics, and nutritional interventions to help clinicians define, track, and restore microbiome function.

Its lead diagnostic tool, GB-0001, is designed to provide a standardized measure of functional gut microbiome health and have a direct impact on clinical decision-making. If approved, GB-0001 would help health care professionals monitor gut health while modifying medication and nutrition, ultimately restoring gut microbiome health

The company is also developing a new kind of treatment, CS-0003. Instead of using antibiotics, which can eliminate both good and bad bacteria, this therapy is designed to block the harmful behavior of bad bacteria while supporting the growth of beneficial ones. It may help reduce serious infections—especially after surgery—without contributing to antibiotic resistance.

32 Biosciences emerged from the University of Chicago's medical research ecosystem, founded by three microbiome experts: Dr. John Alverdy, Dr. Eugene B. Chang, and Dr. Joseph F. Pierre, whose innovative microbiome research and development has been supported by $119 million in National Institutes of Health (NIH) grants.

 Each founder brings a track record of pioneering contributions to gut health, with recognition that includes the American Surgical Association’s Flance-Karl Award (considered one of the world’s most prestigious recognitions of scientific achievement) and the 2025 AGA Distinguished Achievement Award in Basic Science. 

32 Biosciences has recently announced a $6 million round. The company is progressing toward FDA clearance for its gut microbiome diagnostic management tool, which is targeted for late 2026. 

The human microbiome market is projected to expand at a CAGR of 20.42%, growing from $941.215 million in 2025 to $2.38 billion by 2030. As the field moves from research to clinical adoption, 32 Biosciences is building the tools to support that shift.

Feeling like you missed out? The Note offers indirect exposure to innovative companies like 32 Biosciences, giving you a way to participate in the outcomes of venture-backed startups.

Invest in the Note